Priyanka Baloni, PhD

Priyanka Baloni, PhD

Dr. Priyanka Baloni earned her Ph.D. from the Indian Institute of Science, India, and got her postdoctoral training at the Institute for Systems Biology, Seattle, under the mentorship of Drs. Leroy Hood and Nathan Price.

Dr. Priyanka Baloni is an Assistant Professor of Toxicology in the School of Health Sciences and an affiliated member of the Purdue Institute for Integrative Neuroscience at Purdue University. Dr. Baloni has led computational efforts in several large, coordinated projects involving diverse research teams and managing heterogeneous experimental data types in the field of biomedical health sciences. Her expertise spans a wide spectrum of systems biology approaches and multi-omics analyses, including genomics, transcriptomics, metabolomics, and proteomics that lead to biomarker discovery.

Dr. Baloni’s groundbreaking work has resulted in the generation of human brain region-specific metabolic networks, offering invaluable insights into the impact of metabolic alterations in Alzheimer’s disease (AD). She is actively associated with the NIH Accelerating Medicines Partnership – Alzheimer’s Disease (AMP-AD) program, and her research has led to the identification of potential therapeutic targets in AD. Her work on studying altered bile acids and sphingolipid metabolism in AD has led to drug repositioning and filing of patents. Beyond neurodegenerative diseases, Dr. Baloni’s contributions extend to diverse fields, including cancer, SARS-CoV2 infection, aging interventions, and pregnancy complications.

She was an MPI for NICHD grant and currently serving as a co-Investigator in NIA, NIDDK, and NIEHS funded projects. Her research has resulted in several peer-reviewed publications from each project and has received national and international recognition through invited talks at various conferences and symposia.Her group’s research focus is on developing cutting-edge computational approaches to analyze multi-omics data and integrating them with models to identify biomarkers in neurodegenerative diseases.s